Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology

Abstract

AbstractBackgroundAlthough it has been already demonstrated that plasma amyloid‐β (Aβ), phosphorylated tau (p‐tau), and glial fibrillar protein (GFAP) can predict with high accuracy Alzheimer's disease (AD) pathophysiology, no previous study has compared their performance in the same set of individuals. Here, we compare the performance of plasma Aβ42/40, p‐tau, GFAP, and NfL against Aβ and tau PET across the AD spectrum.MethodWe used the ROC curve to test the predictive performance of Simoa plasma Aβ42/40, p‐tau (at threonine 181 and 231), NfL, and GFAP to identify Aβ and Pau PET positivity in 138 cognitive unimpaired (CU) and 87 cognitive impaired (CI) from the McGill TRIAD cohort. Pearson correlation and linear regression tested the association between markers.ResultWe showed that plasma p‐tau231, p‐tau181, GFAP, and NfL correlated with each other (Figure 1), while Aβ42/40 did not. In CU, voxel‐wise linear regressions (Figure 2A) showed that p‐tau231, p‐tau181, and GFAP concentrations were significantly associated with Aβ‐PET (Figure 2A). While for Tau‐PET (Figure 2B), there was a significant association only with p‐tau231 and p‐tau181 (Figure 2B). P‐tau231 outperformed the other plasma biomarkers to identify both Aβ‐ and Tau‐PET positivity (AUC 0.877 and 0.796, respectively) in CU individuals. In CI, Aβ‐ and Tau‐PET were significantly associated with p‐tau231, p‐tau181, and GFAP, whereas NfL was only associated with Tau‐PET. The discriminative accuracy of GFAP in identifying both Aβ‐PET and Tau positivity (AUC 0.936 and 0.944, respectively) outperformed the other plasma biomarkers in CI individuals (Figure 3, Table 1).ConclusionWe showed that plasma p‐tau231, a novel biomarker of early AD, best depicted AD pathophysiology in CU individuals. Interestingly, GFAP, an astrocyte reactivity marker, was better associated with brain Aβ and tau pathologies than plasma p‐tau and Aβ markers in CI individuals. Our results highlight that the performance of the novel plasma biomarkers of amyloid, tau and neuroinflammation to detect brain AD pathophysiology is disease stage specific.